Esophageal carcinoma is a common malignant gastrointestinal tumor in China, with poor prognosis. Lymph node metastasis and distant metastasis may occur at early stage. In China, most cases of esophageal cancer were diagnosed at advanced stage and can not be treated by radical surgery [13] . Nowadays, esophageal carcinomas are mainly treated with multidisciplinary sequential or simultaneous treatment composed by surgery, radiotherapy and chemotherapy. Certain progression was achieved in treating advanced esophageal carcinoma by chemotherapy in recent years. Accumulating data indicate the response rate of patients with advanced gastric or gastroesophageal junction adenocarcinoma treated by DCF regimen [docetaxel plus cisplatin (DDP) and 5fluorouracil (5FU)] was up to 54% 86% [46] . Fortythree patients with pathologically confirmed advanced esophageal carcinoma were treated with docetaxel plus nedaplatin and 5FU (DNF regimen) in Hexian Memorial Hospital at Panyu District of Guangzhou between August, 2003 and February, 2009. The results were as follows.
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All the 43 patients had either distant metastasis or postoperative recurrence, or unresectable lesions, and had at least one measurable lesion which was pathologically confirmed. Of the 43 patients, 29 were men and 14 were women, aged 35 to 72 years old, with a median of 55; 17 had well differentiated squamous cell carcinoma, 12 had poorly differentiated squamous cell carcinoma, 13 had adenocarcinoma, and 1 had adenosquamous carcinoma; 26 had cervical lymph node metastasis, 33 had mediastinal and lung metastasis, 8 had celiac lymph node metastasis, 13 had liver metastasis; 17 had 1 metastatic lesion, 19 had 2 metastatic lesions, 7 had 3 or more metastatic lesions; 9 underwent radical or palliative surgery (7 of them received adjuvant chemotherapy), 4 had recurrence after radiotherapy, and 30 were naive patients KPS score of no less than 60, with an estimated survival of more than three months. The functions of patients' heart, lungs, liver and kidneys were normal. No history of other malignancy was recorded. ). The cycle was repeated every three weeks. Treatment efficacy was evaluated every two weeks according to the WHO standards. All patients received at least two cycles of chemotherapy. Tropisetron was routinely adopted before chemotherapy to avoid vomiting. Dexamethasone was routinely used before docetaxel infusion. Chemotherapy would be postponed, no more than 2 weeks, when patient's neutrophil count was less than 1.5 伊 10 9 /L or platelet count was less than 75 伊 10 9 /L. The chemotherapy dose would be reduced by 25% if occurring grade III/IV febrile neutropenia, neurotoxicity or grade IV mucosal response. Treatment would be terminated if grade IV neutropenia appeared twice. Granulocyte colonystimulating factor (GCSF) would be used while appearing grade III/IV myelosuppression.
According to WHO Efficacy Evaluation Criteria, treatment efficacy was evaluated as complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD). Adverse events were recorded according to NIH Common Toxicity Criteria (CTC3.0). Timetoprogression (TTP) was defined as the time from the beginning of receiving chemotherapy to disease progression. Overall survival (OS) was defined as the time from the beginning of receiving chemotherapy to death or the latest followup visit. The patients were followedup by telephone or questionnaire till June 1st, 2009. No patient was lost to follow. The median followup time was 10.3 months. The efficacy was evaluable in all patients. SPSS17.0 software was used for statistical analysis. The KaplanMeier method was used to calculate the median survival time (MST), TTP and to draw survival curves.
The 43 patients received 28 cycles of chemotherapy (median, 3 cycles) for a total of 144 cycles. Among them, 2 (4.65% ) achieved CR, 25 (58.14% ) achieved PR, 9 (20.93% ) had SD, and 7 (16.28%) had PD. The overall response rate was 62.79% . Among the 7 patients who had previously received chemotherapy, 4 (9.3% ) achieved PR, 2 (4.65% ) had SD, 1 (2.33% ) had PD. The TTP was 201 days and the MST was 310 days.
Grade III/IV adverse events mainly included neutropenia (20.93% , 2 patients had febrile neutropenia), thrombocytopenia (6.98%) and anemia (6.98%). The nonhematologic toxicity was usually mild. No grade III/IV peripheral nerve toxicity occurred. Gastrointestinal reactions mostly manifested as grade I/II nausea and vomiting (65.12% ). The mucositis was mild. No patient quitted treatment due to gastrointestinal reaction. The occurrence rate of alopecia was 55.18% , and only 3 (6.98% ) patients had grade I/II alopecia. Bilirubin was slightly elevated due to liver and kidney toxicity, only 1 (2.33%) patient had grade III toxicity (Table  1 ). The treatment for 10 patients was postponed for no more than 1 week due to toxicity of chemotherapy. Two patients had chemotherapy dose reduction due to toxicity. One died of chemotherapyrelated events. Among the 7 patients who had previously received chemotherapy mostly had grade I/II adverse events, only 1 (2.33% ) had grade III gastrointestinal reaction (nauseating and vomiting), 2 (4.65%) had grade III neutropenia. Chemotherapy is one of the main treatments for advanced esophageal carcinoma. Accumulating data indicated the efficacy of platinumbased chemotherapy plus 5FU on esophageal carcinoma was 20% 50% [7, 8] . In recent years, the efficacy of some anticancer drugs, such as paclitaxel, vinorelbine, irinotecan, gemcitabine, and so on, used in combination with 5FU, on esophageal carcinoma was up to 33% 75% [812] . The MST of patients received concurrent chemoradiotherapy was 1235 months [1315] . However, the adverse events, such as myelosuppression, gastrointestinal reaction, mucositis, were increased , while no significant increase in OS rate was observed [10] . Hence, it is imperative to seek for regimens and drugs with high efficiency and low toxicity. Docetaxel, a semisynthetic taxane derivative, has high antitumor activity and a broad antitumor spectrum with comprehensive cytotoxicity against a variety of solid tumors. The efficacy of docetaxel alone on esophageal carcinoma was about 20% [16, 17] . Huang . [18] reported that the response rate of 65 patients with advanced or refractory and relapsed nasopharyngeal carcinoma after treatment of docetaxel, DDP plus 5FU was 72.5% , with a CR rate of 9.8% . Wu . [19] compared the efficacy and toxicity of FOLFOX4 regimen and DP (O)F regimen (docetaxel, oxaliplatin/DDP plus 5FU) in treating 70 cases of advanced gastric carcinoma, and found no obvious difference in objective response rate, TTP and MST between the two groups, and observed an increase in the occurrence of grade III/IV neutrophils in group DP(O)F as compared with group FOLFOX4.
Nedaplatin, the secondgeneration platinum anticancer drug, is mainly used in treating head and neck cancer and small cell lung cancer [2023] . It has a broad anticancer spectrum, high efficiency, low renal and gastrointestinal toxicity, good synergetic effect when being combined with other chemotherapeutic drugs, no complete crossresistance with cisplatin, and can be used easily without hydration. Nedaplatin has synergetic effect with 5FU and docetaxel [2730] . Watanabe .
[31] reported that they had cured patients with advanced esophageal carcinoma using nedaplatin, 5FU plus concurrent radiotherapy. Kato . [32] had treated patients with advanced and unresectable esophageal squamous cell carcinoma by nedaplatin, 5FU plus radiotherapy, and achieved an overall response rate of 77%, the 1 and 2year survival rates were 30.7% and 10.2% , MST reached to 10.1 months. Recently, Matsutani . [33] reported that a 69yearold patient with advanced esophageal cancer who had been treated by DNF plus radiotherapy achieved CR for 20 months , and only had grade II neutropenia and gastrointestinal reaction. Fujita [34] had compared the efficacy of DN regimen (docetaxel/nedaplatin) and FP regimen (cisplatin/5FU) on recurrent esophageal cancer and found that the response rates of the two groups were 36.3% and 10.0%, respectively.
Compared to literature, we appropriately increased the dose of docetaxel and nedaplatin, and achieved an overall response rate of 62.8%, a median TTP of 201 days and a median survival of 310 days. In our study, the hematologic toxicity caused by DNF regimen was mainly grade I/II, the occurrence of grade III/IV toxicity was in balance with those reported in literature, and most cases of grade III/IV toxicity were alleviated after GCSF and symptomatic treatment. The treatment of 10 patients was postponed due to toxicity of chemotherapy, but no more than 1 week. Two patients had chemotherapy dose reduction because of chemotherapy toxicity. Only 1 patient died of intracranial hemorrhage secondary to chemotherapycaused grade IV thrombocytopenia. In our study, 13 patients had previously received chemotherapy or radiotherapy, and the symptoms of severe nausea/vomiting, and neutropenia were obvious among these patients.
Our study suggests that DNF regimen is effective and well tolerated as firstline chemotherapy for patients with advanced esophageal carcinoma. Further multicenter study with large sample is needed.
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